Dr Goldberg is a Gastroenterologist at Monash Health and a research fellow at School of Clinical Sciences. Dr Goldberg treats patients suffering from inflammatory bowel disease and is interested in developing novel treatments for this debilitation condition.
During her PhD at King’s College London (2019), Dr Goldberg worked to develop a regulatory T cell (Treg) based therapy for patients with Crohn’s Disease. This therapy uses the patients’ own immune cells to turn off the inflammation driving their disease. This novel treatment is currently a Phase 1 trial across the United Kingdom. Dr Goldberg has published her research in top tier Gastroenterology journals, including Gut, Gastroenterology and Nature Reviews Gastroenterology. She was the recipient of the British Society of Gastroenterology Best Scientific Abstract Award as well as the Society of Mucosal Immunology – Rising Stars in Mucosal Immunology award.
Since returning to Australia, Dr Goldberg has worked to form collaborative research networks to bring this paradigm changing therapy to the Australian patient population. Her work is currently supported by the school of clinical sciences career development fellowship and a Crohn’s and Colitis Australia Research Prize. As part of her clinical work, Dr Goldberg is an investigator on a number of industry led Phase 2/3 trials, thus always ensuring her patients have access to cutting edge therapies.
- Adaptive immunity in inflammatory bowel disease
- Innate immunity in inflammatory bowel disease
- Cell based therapies for inflammatory bowel disease
Find out more about Dr Rimma Goldberg.